Multiple system atrophy is a rare progressive neurodegenerative disorder characterized by autonomic failure plus parkinsonian and/or cerebellar motor features. Disease progression leads to increasing disability and reduced survival.
Alpha-synuclein biomarkers in saliva, skin, and CSF show diagnostic promise for Parkinson's disease, with seed amplification assays demonstrating high sensitivity and specificity. Salivary gland biopsies and oral brushings are being studied as less invasive detection methods, though clinical implementation still faces challenges.
Recent studies associate blood biomarkers with brain atrophy and cognitive decline in Alzheimer's disease, while new DNA aptamers, retinal imaging, and speech analysis advance neurodegeneration detection and monitoring.
Rare diseases affect an estimated 25-30 million Americans, yet 95% lack FDA-approved treatments. Families affected by conditions like SLC6A1-related disorders and Anti-IgLON5 Autoimmune Encephalitis voice concerns about drug pricing policies that could slow medical innovation. Advocates urge lawmakers to protect research investment while sharing stories of diagnostic challenges and treatment breakthroughs.
Quantitative and functional MRI techniques are gaining traction as biomarkers in neurodegenerative diseases. A consensus statement provides MRI endpoint recommendations for clinical trials in hereditary ataxias like SCA and Friedreich ataxia. Separately, research shows resting-state fMRI can distinguish subtypes of multiple system atrophy and may improve early diagnosis.
Alterity is preparing for a mid-2026 end-of-Phase II FDA meeting for ATH434 in Multiple System Atrophy. Phase II data showed clinically meaningful and statistically significant effects, with safety comparable to placebo.
Teva and Sanofi reported durable 44-week efficacy for duvakitug in inflammatory bowel disease, while the FDA accepted Teva's application for TEV-749, a once-monthly olanzapine injection for schizophrenia.
iRegene Therapeutics has dosed the first U.S. patient in a Phase IIa trial of NouvNeu001 for Parkinson's disease and enrolled the first patient in a China trial of NouvNeu004 for Multiple System Atrophy.
BioArctic reported net revenues of SEK 184.0 M for Q4 2025, driven by Leqembi royalties and Novartis partnership income. Leqembi received multiple regulatory approvals and submissions across global markets during the quarter.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07774585 |
A Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy |
NOT_YET_RECRUITING | PHASE1 |
| NCT07729852 |
Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France |
NOT_YET_RECRUITING | PHASE2 |
| NCT07657520 |
High-Altitude Neurodegeneration Cohort (HANC) Study |
RECRUITING | |
| NCT07644013 |
Prospective Multicenter Registry Study of Multiple System Atrophy in China |
RECRUITING | |
| NCT07604883 |
Early Molecular Biomarkers for Differentiating Parkinsonian Syndromes |
NOT_YET_RECRUITING | |
| NCT07570212 |
Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders |
RECRUITING | NA |
| NCT07531433 |
Post-Trial Access to ATH434 for Patients With Multiple System Atrophy |
AVAILABLE | |
| NCT07518810 |
Efficacy and Safety of Butylphthalide in the Treatment of Multiple System Atrophy |
NOT_YET_RECRUITING | PHASE2/PHASE3 |
| NCT07476352 |
Expansion Study of ALT001 in Patients With Multiple System Atrophy |
NOT_YET_RECRUITING | EARLY_PHASE1 |
| NCT07392411 |
Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers |
RECRUITING |
